




RealRate

PHARMACEUTICAL 2023

Theriva Biologics Inc
Rank 152 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Theriva Biologics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theriva Biologics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Theriva Biologics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 317%, being 72% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	45,520
Cost of Goods Sold	0
Intangible Assets	24,675
Liabilities, Current	7,060
Liabilities, Non-Current	1,187
Other Assets	1,321
Other Compr. Net Income	-679
Other Expenses	-1,425
Other Liabilities	9,050
Other Net Income	471
Other Revenues	0
Property and Equipment	345
Research and Development	11,723
Selling, General and Administrative Expense	9,858

Output Variable	Value in 1000 USD
Assets	71,861
Liabilities	17,297
Expenses	20,156
Revenues	0
Stockholders Equity	54,564
Net Income	-19,685
Comprehensive Net Income	-20,024
BaseVar	55,232
ECR before LimitedLiability	222%
Economic Capital Ratio	317%